| Today’s Big NewsNov 14, 2023 |
| By Max Bayer Developing a functional cure for hepatitis B has proved elusive, with the pipeline of new clinical therapies incrementally growing in the last seven years. More midstage readouts and a handful of new deals are adding much-needed optimism that progress is being made. |
|
|
|
By Nick Paul Taylor GSK spinout Autifony Therapeutics has drummed up a collaboration with Jazz Pharmaceuticals, securing up to $770.5 million to discover and develop drug candidates against two ion channel targets associated with neurological disorders. |
By James Waldron Telix Pharmaceuticals has offered to pay $33.1 million for Qsam Biosciences so the Australian biotech can get its hands on a phase 1 radiopharmaceutical for bone cancer. |
Sponsored by Questex Fierce Biotech sits down with digital marketing leaders to discuss this year's most innovative topics at Fierce Biotech Summit and New Product Planning |
|
Reduce sequence artifacts that dampen variant calling sensitivity. Prepare highly complex libraries in under 1.5 hours, and minimize damage and loss with precious low-input and FFPE material. Learn more.
|
|
By James Waldron Four months after a safety signal blew Theseus Pharmaceuticals’ quest to develop a gastrointestinal stromal tumor treatment off course, the biotech is shrinking its head count by almost three-quarters. |
By Nick Paul Taylor Ipsen and Genfit have shown off the data they believe can finally secure approval of their liver disease candidate elafibranor. The publication puts meat on the bones of an earlier data drop, providing a closer look at how the therapy holds up against Intercept Pharmaceuticals’ Ocaliva and CymaBay Therapeutics’ own challenger. |
By Helen Floersh A small molecule alleviates four different types of acute and chronic pain in rodents, with none of the side effects associated with widely prescribed non-opioid painkiller gabapentin. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Fraiser Kansteiner Pfizer plans to cut approximately 500 roles and ax its Pharmaceutical Sciences Small Molecule capabilities at its site in Sandwich in Kent in the U.K. The move is a consequence of Pfizer’s enterprisewide cost realignment program, which the drugmaker unveiled in mid-October. |
By Paige Minemyer The White House Initiative on Women's Health Research will be led by first lady Jill Biden, the administration said Monday. |
By Nick Paul Taylor Is understanding the needs and behavior of healthcare providers on your to-do list for 2024? If so, you’re far from alone, with an EPG Health study finding collecting such insights is the No. 1 strategic HCP engagement priority for the coming year. |
By Andrea Park The C-suite makeover is aimed at emphasizing ResMed’s focus on product development, profitable growth and strengthened branding, according to a company announcement. |
Fierce podcastsDon’t miss an episode |
| In this episode of “The Top Line,” we explore the next potential wave of mental health therapy: psychedelics. |
|
|---|
|
|
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
